4.71
+2.84%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Evolent Health
From its filings with the US Securities and Exchange Commission
Evolent Health is based in Arlington, Virginia and is incorporated in Delaware. Its shares trade on NYSE under the ticker EVH. The SEC classifies its business as management services. In the fiscal year to 31 December 2025, it reported revenue of $1.88bn and a net loss of $534.5m. At that date it held total assets of $1.90bn and shareholders' equity of $415.2m.
Evolent was founded in 2011 by members of our management team, UPMC, an integrated delivery system in Pittsburgh, Pennsylvania, and The Advisory Board Company, to enable providers to pursue a value-based business model and evolve their competitive position and market opportunity. Since that time, we have grown both organically and through acquisitions. Our acquisitions have been focused on companies with extensive experience assisting customers in managing the large and complex specialties of oncology, cardiology, radiology, musculoskeletal, physical medicine, and genetics care.
We have one operating segment and one reportable segment as our chief operating decision maker (“CODM”), who is our Chief Executive Officer, assesses the performance of our operations, develops strategy and reviews financial information on a consolidated basis for purposes of evaluating financial performance and allocating resources.
The majority of our revenues derive from our primary solution, Specialty Care Management Services, however we also offer additional administrative services to our customers. From time to time, we package our solutions under various go-to-market brand names to create product differentiation. Our partners may engage us to provide one, or multiple types of solutions, depending on their specific needs.
Quoted from its 10-K, filed 25 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Technology
- Listed since
- 5 Jun 2015
- Employees
- 4,200
- Website
- evolenthealth.com ↗
- Head office
- 1812 NORTH MOORE ST, SUITE 1705, ARLINGTON, VA, 22209
- Incorporated in
- DE
- Classification
- Services-Management Services
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Richard JelinekIndependent Chairman of the Board$265,250
- Mr. Daniel MccarthyPresident$7.5m
- Mr. Seth BlackleyChief Executive Officer, Co-Founder, Director, since 2011$11.1m
- Mr. John JohnsonChief Financial Officer$4.8m
- Ms. Emily RaffertyChief Operating Officer$2.0m
- Mr. Aammaad ShamsChief Accounting Officer$634,883
- Mr. Jonathan WeinbergGeneral Counsel$2.0m
- Dr. David LimChief Clinical Officer
- Mr. John WayChief Financial Officer, Performance Suite
- Mr. Shawn GuertinDirector
- Dr. Toyin AjayiIndependent Director$265,250
- Mr. Craig BarbaroshIndependent Director$282,500
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 44
- Environment
- 14
- Social
- 41
- Governance
- 76
- Women in the workforce
- 68%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Evolent Health Inc possesses several notable strengths that contribute to its success and market position. These strengths include:
Weaknesses
- Although Evolent Health Inc has established itself as a prominent player in the healthcare industry, it also faces certain weaknesses that can hinder its growth and performance. These weaknesses include:
Opportunities
- Evolent Health Inc can capitalize on various opportunities in the healthcare industry to further enhance its growth and market position. These opportunities include:
Threats
- Evolent Health Inc faces several threats that pose challenges to its growth and competitive position within the healthcare industry. These threats include:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.